Trial Information
A Multi-Center Study to Evaluate the Safety and Efficacy of a Urine DEK ELISA in Diagnosis of Subjects With Bladder Cancer
Inclusion Criteria:
- Patients who are at least twenty-five (25) years of age with hematuria, dysuria or
other irritative voiding symptoms, without evidence of other causative factors such
as infections or stones.
Exclusion Criteria:
- Females who are pregnant (ascertained by history)
- Females who are menstruating or within three (3) days of their last menstruation
- Patients who have undergone invasive procedures of the urogenital tract in the past
two (2) months
- Patients with a history of transitional cell carcinoma (TCC) of the urinary tract
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Principal Investigator
Jason Trama, PhD
Investigator Role:
Study Director
Investigator Affiliation:
Medical Diagnostic Laboratories, LLC
Authority:
United States: Institutional Review Board
Study ID:
ONC04
NCT ID:
NCT01563796
Start Date:
March 2012
Completion Date:
December 2013
Related Keywords:
- Hematuria
- Dysuria
- Bladder Cancer
- bladder cancer
- TCC
- urine
- protein ELISA
- Urinary Bladder Neoplasms
- Dysuria
- Hematuria
Name | Location |
Staten Island University Hospital |
Staten Island, New York 10305 |